Receptor-tethered orthogonal IL-2 enhances regulatory T cell therapy.

Tethered orthogonal IL-2 engineered into Tregs enhances their survival and prevents autoimmune diabetes in mice by enabling self-sustaining autocrine signaling.

• Why it matters: Limited Treg persistence due to insufficient IL-2 hampers their therapeutic potential in controlling immune overactivation, necessitating targeted strategies to improve Treg stability and function.
• What they did: Researchers engineered Tregs with a receptor-tethered orthogonal IL-2, inserting the construct into the Foxp3 locus to promote Treg-specific self-reinforced expression and autocrine signaling, tested in a mouse autoimmune diabetes model.
• The result: This approach increased Treg markers and persistence without external IL-2, leading to improved prevention of autoimmune diabetes, and offers a safe, effective method to enhance Treg therapy efficacy.